Maxim Group analyst Michael Diana has maintained their neutral stance on SURG stock, giving a Hold rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Diana’s rating is based on several factors that reflect the current uncertainties surrounding SurgePays’ business model and financial outlook. The company’s recent financial results showed a decline in revenue and a net loss, which were below market expectations. This underperformance was partly due to the delayed impact of their Lifeline program, which only began to gain traction in the third quarter of 2025.
Furthermore, while SurgePays has initiated strong revenue guidance for 2025, there are concerns about the sustainability of the recent sign-ups and the overall economics of the Lifeline program. The program involves upfront costs for smartphones and sales commissions, which could impact cash flow and profitability. Until there is more clarity on these issues, and given the current balance sheet constraints, Diana has opted to maintain a Hold rating on the stock.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.00 price target.
SURG’s price has also changed dramatically for the past six months – from $1.460 to $2.190, which is a 50.0% increase.